DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome.
5 patients suffering from von Willebrand's syndrome were treated with DDAVP administered intravenously or intransally. The concentration of F. VIII-related activities (F. VIII:C, F. VIII R:AG, F. VIII R:WF), as well as the mobility of F. VIII R:AG in crossed immunoelectrophoresis and the alterations of bleeding time were continuously monitored. DDAVP induced both quantitative and qualitative changes of F. VIII-related properties. The bledding time was markedly reduced for some hours. The therapy was well tolerated and should be submitted to further clinical trials as a possible way to avoid the disadvantages connected with the transfusion of blood components.
D000293:Adolescent; D001127:Arginine Vasopressin / Q000494:pharmacology*; D001760:Bleeding Time; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology* / Q000627:therapeutic use; D005169:Factor VIII / Q000378:metabolism*; D005260:Female; D006801:Humans; D007122:Immunoelectrophoresis; D008297:Male; D008875:Middle Aged; D014842:von Willebrand Diseases / Q000097:blood* / Q000188:drug therapy
D001127:Arginine Vasopressin; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin